OR2T12

Across TCGA pan-cancer cohorts, OR2T12 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated OR2T12 data layer compared with 6 for mutation status.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher OR2T12 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR2T12 expression acts as an unfavorable survival marker, although some lineages such as KIRC show a favorable association.

UCS, STAD, and GBM are the cancer types where OR2T12 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Tertile	All	0.001	0.690	<.001	108	view →
STAD	OS	Tertile	All	0.199	0.445	.006	72	view →
GBM	OS	Tertile	All	0.033	0.416	<.001	36	view →
OV	OS	Tertile	IV	0.233	0.788	<.001	36	view →
COAD	OS	Tertile	II,III,IV	0.183	0.788	.007	27	view →
KIRC	DFS	Tertile	III,IV	1.000	0.454	.033	24	view →
KIRP	OS	Tertile	II,III,IV	0.178	0.743	.013	18	view →
UCEC	OS	Tertile	All	0.840	0.928	.012	12	view →
THCA	DFS	Tertile	IV	0.075	0.807	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

OR2T12–UCS (OS)

Open the UCS breakdown →